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Microtubule-associated protein tau (MAPT) hyperphosphorylation and aggregation,
are two hallmarks of a family of neurodegenerative disorders collectively referred to
as tauopathies. In many tauopathies, including Alzheimer’s disease (AD), progressive
supranuclear palsy (PSP) and Pick’s disease, tau aggregates are found associated
with highly sulfated polysaccharides known as heparan sulfates (HSs). In AD, amyloid
beta (Aβ) peptide aggregates associated with HS are also characteristic of disease.
Heparin, an HS analog, promotes misfolding, hyperphosphorylation and aggregation
of tau protein in vitro. HS also provides cell surface receptors for attachment and
uptake of tau seeds, enabling their propagation. These findings point to HS-tau
interactions as potential therapeutic targets in tauopathies. The zebrafish genome
contains genes paralogous to MAPT, genes orthologous to HS biosynthetic and
chain modifier enzymes, and other genes implicated in AD. The nervous system in
the zebrafish bears anatomical and chemical similarities to that in humans. These
homologies, together with numerous technical advantages, make zebrafish a valuable
model for investigating basic mechanisms in tauopathies and identifying therapeutic
targets. Here, we comprehensively review current knowledge on the role of HSs in tau
pathology and HS-targeting therapeutic approaches. We also discuss novel insights
from zebrafish suggesting a role for HS 3-O-sulfated motifs in tau pathology and
establishing HS antagonists as potential preventive agents or therapies for tauopathies.
Keywords: heparan sulfate, glycosaminoglycans, tauopathy, tau, Alzheimer’s disease, zebrafish, drug discovery
HEPARAN SULFATE PROTEOGLYCANS
Structure and Biosynthesis
Glycosaminoglycans (GAGs), formerly called mucopolysaccharides, are a major class of anionic
polysaccharides, consisting of unbranched and often long polysaccharide chains made of
disaccharide units. Most GAGs are bound to core proteins, forming proteoglycans (PGs), which
are important components of extracellular matrices. All extracellular matrices contain PGs, but
these glycoproteins are also found in membrane-bound secretory granules and in cell nuclei.
PGs are evolutionarily ancient and are found in all Bilateria species (organisms with left-
right symmetry). So far, five structurally different GAG species have been described: heparan
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sulfate (HS), chondroitin sulfate (CS), dermatan sulfate (DS),
keratan sulfate (KS) and hyaluronan or hyaluronic acid (HA).
While heparin, a highly sulfated HS, is mainly produced by
connective tissue-type mast cells and bipotential glial progenitor
cells, HS is synthesized by all cell types (Couchman and Pataki,
2012; Lindahl et al., 2017). In the zebrafish (Danio rerio), HS
is synthetized in developing embryos, larvae and adults (Zhang
et al., 2009).
Glycosaminoglycans synthesis starts in the endoplasmic
reticulum (ER), with the formation of a tetrasaccharide linker
(Xyl-Gal-Gal-GlcA) bound to the core protein via a serine
residue. During linker formation, xylose (Xyl) is first attached
by a xylosyltransferase (XT); galactosyl-transferases I and II
(GT I and II) then transfer two galactoses (Gal) from UDP-Gal
to xylose, and finally, glucoronic acid (GlcA) is transferred
from UDP-GlcA by glucuronosyl-transferase I (GlcAT). After
the formation of the linker, GAG biosynthesis takes different
routes for CS/DS or heparin/HS synthesis. Synthesis of CS/DS
chains first involves the transfer of N-acetylgalactosamine
(GalNAc) by GalNAc transferase to the terminal GlcA,
while that of heparin/HS chains depends on the transfer of
N-acetylglucosamine (GlcNAc) by GlcNAc transferase. The
GAG chains are then elongated by sequential addition of
repeated disaccharide units composed of an amino sugar,
[N-acetylgalactosamine (GalNAc) or N-acetylgalactosamine
(GalNAc)], and a uronic acid [glucoronic acid (GlcA) or iduronic
acid (IdoA)]. In HS and heparin, the repeated disaccharide unit
comprises N-acetylglucosamine and glucoronic acid residues.
EXT enzymes mediate HS/heparin chain elongation (Kreuger
and Kjellén, 2012).
After their synthesis, GAG chains are modified in the
Golgi apparatus by different enzymes. All HS chain modifier
enzymes have been identified in zebrafish (Bink et al., 2003;
Chen et al., 2005; Ghiselli and Farber, 2005; Cadwallader
and Yost, 2006a,b, 2007; Filipek-Górniok et al., 2015). Major
modifications on the HS chains are sulfations, which are mediated
by two classes of sulfotransferases in a hierarchical manner.
The expression patterns of these enzymes are characterized
in zebrafish through early developmental stages (0–48 hpf).
First, the N-deacetylase/N-sulfotransferases (NDSTs) replace the
acetyl group in GlcNAc by a sulfate group. Five NDST genes
(ndst1a, ndst1b, ndst2a, ndst2b, and ndst3) have been identified
in zebrafish. All isoforms are expressed in various brain regions
during early zebrafish development, while a distinct isoform
(ndst3) is expressed in the spinal cord (Filipek-Górniok et al.,
2015). HS chains can be further modified through epimerization
of GlcA into iduronic acid (IdoA) by C-5 epimerase. The
zebrafish C-5 epimerases Glce-A and Glce-B are expressed in
brain through early embryonic development (Cadwallader and
Yost, 2007).
The second class of sulfotransferases comprises the HS
O-sulfotransferases (OSTs) 2-OST, 6-OST, and 3-OST. Zebrafish
2-OST or HS2ST is expressed in all brain regions in early
developmental stages. Of the four zebrafish 6-OSTs or HS6STs
(6-OST-1a, 6-OST-1b, 6-OST-2, and 6-OST-3) all are expressed
in the brain in early development, while only 6-OST-1a and
6-OST-1b isoforms are expressed in the spinal cord (Cadwallader
and Yost, 2006b). Comparison of HS structure between adult
zebrafish and porcine intestine revealed similar global structures.
Differences were documented as higher 2-O-sulfated iduronic
acid (IdoA2S) content and lower levels of GlcA (Zhang et al.,
2009).
It has been suggested that the evolutionary origin of the Hs3sts
goes back to a common ancestor of bilaterians and cnidarians
in the early eumetazoan evolution. Trichoplax, a placozoan
identified as a sister clade to bilaterians and cnidarians, has no
Hs3st homologs, but expresses all the other HS sulfotransferases.
Invertebrates express fewer Hs3st isozymes than vertebrates.
Hydra expresses one Hs3st, whereas Nematostella (sea anemone),
belonging to the Cnidarian phylum, expresses two Hs3sts. The
Hs3st enzymes in Hydra and Nematostella share near 50% amino
acid sequence identity with human Hs3sts. Strongylocentrotus
(sea urchin) and Planaria (flatworm) express a single Hs3st,
whereas Drosophila (fruit fly) and Caenorhabditis (nematode)
have two Hs3st. Vertebrates express a greater number of Hs3sts.
Homo and other mammals express 7 Hs3sts, while Danio
(zebrafish) expresses 8 (Thacker et al., 2014). 3-O-Sulfated
disaccharides and tetrasaccharides have been identified in HS
from zebrafish embryos, which were diminished by morpholinos
directed against specific 3-ost genes. During early cleavage stages
in the zebrafish, 3-OST enzymes are encoded by maternally
deposited mRNAs, which are evenly distributed throughout
the embryos. By contrast, during later stages, and particularly
in the developing brain, the zebrafish Hs3st genes display
a complex combinatorial expression profile with each gene
showing a unique and cell-type specific expression pattern. The
3ost1 transcripts are ubiquitously accumulated to high levels
during early cleavage stages prior to becoming restricted to
head and anterior somites by 24 hpf. In 48 hpf embryos,
3ost1 expression is restricted to head, gut and pectoral fin.
Expression of the 3ost2 gene is detected from 24 hpf onward in
the brain and otic vesicle. At 48 hpf, 3ost2 is expressed in all
major brain areas, as well as in the olfactory region. Zebrafish
3ost3X and -3Z are the orthologs of the mammalian 3-OST-
3a and -3b genes, respectively. 3ost3X transcripts are evenly
distributed during early cleavage stages and are restricted to
hindbrain and spinal cord from 36 hpf onward. By contrast,
while expression of the 3ost3Z gene is not detected during early
cleavage stages, by 48 hpf it is transcribed in telencephalon,
tectal regions, hindbrain, and spinal cord. 3ost4 RNAs are
maternally expressed and ubiquitously accumulated in early
cleavage stage embryos, before being specifically transcribed in
midbrain, hindbrain, olfactory epithelium and otic vesicle by
48 hpf onward. Similarly, ubiquitous accumulation of maternal
3ost5 transcripts is detected in early cleavage and embryonic
stages, while from mid-somitogenesis onward, these RNAs are
specifically transcribed in forebrain, midbrain and spinal cord
neurons. Distribution of 3ost6 transcripts is detected during
early cleavage stages, while from 36 hpf onward these RNAs are
expressed in the hindbrain. Finally, the 3ost7 gene is expressed
during early cleavage stages and becomes restricted to brain
neurons by 48 hpf (Cadwallader and Yost, 2006a). The zebrafish
3ost2 and 3ost3 generate receptors for herpes simplex virus 1
(HSV1) entry, highlighting the functionality and similarity of
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zebrafish neuronal 3-O-sulfated motifs to those found in humans
(Antoine et al., 2014).
Heparan sulfate PGs (HSPGs) comprise one or more HS-
sulfated GAG chains covalently linked to a core protein. 17
distinct types of HSPGs have been identified, which are classified
into three groups based on their locations: (i) syndecans and
glypicans (membrane HSPGs), (ii) agrin, perlecan, and type-
XVIII collagen (secreted extracellular matrix HSPGs), and (iii)
serglycin (secretory vesicle HSPG) (Lindahl et al., 2017). Agrin
also occurs as a transmembrane proteoglycan resulting from
alternative splicing (Burgess et al., 2000; Neumann et al., 2001).
The structure and function of zebrafish syndecan-4, required for
neural crest migration, closely resembles that found in higher
vertebrates (Whiteford et al., 2008). Using brains of BACE-1
deficient zebrafish, glypican-1 is identified as a substrate for
the enzyme. BACE-1 is implicated in pathogenesis of AD by
contributing to generation of Aβ peptide (Hogl et al., 2013).
Heparan sulfate chains of HSPGs can also be modified
post-assembly by several enzymes. In particular, the shortening
and degradation of HS chains involve heparanase (HPSE), and
the removal of sulfate motifs by SULFs (a family of plasma
membrane endosulfatases) entails finer modifications. A single
gene orthologous to human heparanase is found in zebrafish
(Wei and Liu, 2014). Orthologs to mammalian SULFs have
been identified in zebrafish; they consist of three genes, all
expressed in the central nervous system (CNS) (Gorsi et al.,
2010). PG degradation is mediated by their internalization, which
induces endolytic cleavage of the core protein by proteases
and degradation of heparan sulfate chains by heparanase and
endo-β-glucuronidase. Complete degradation of the remaining
small HS chains takes place in lysosomes and involves a
series of exoglycosidases and sulfatases (Lamanna et al., 2008;
Lindahl et al., 2017). The ortholog of the human iduronate-
2-sulfatase in zebrafish, whose defects are responsible for
mucopolysaccharidosis type II (MPS II), has been identified
(Moro et al., 2010). The identification of HSs in zebrafish,
together with an array of orthologs for HS biosynthetic and
chain modifier enzymes in the nervous system, makes zebrafish
a model organism well-suited for the study of HS contribution to
tauopathies.
HS-Protein Interactions
Heparan sulfates can bind non-covalently to a variety of proteins.
An array of heparin-binding proteins have been identified, many
of which interact with HSs under physiological conditions and
modulate their biological activities (Bishop et al., 2007; Ori,
2008; Xu and Esko, 2014). Protein-HS interactions promote
protein presentation, protection and stabilization, as well as
conformational changes and oligomerization (Thacker et al.,
2014). The conformation of GAG chains and the negative charges
provided by the sulfate groups and uronic acid epimers constitute
the binding site for positively charged amino acids of heparin-
binding proteins (Lindahl and Li, 2009; Sarrazin et al., 2011). The
ligand-binding sites of HSPGs rely on the orientation of carboxyl
groups and organization of sulfate groups (Sarrazin et al., 2011).
In particular, the sulfation pattern of HSPGs, which is more
diverse than other GAG chain modifications, plays an essential
role in the specificity of the binding sites of HSPGs to heparin-
binding proteins (Aviezer et al., 1994; Sanderson et al., 1994;
Herndon et al., 1999). Moreover, it has been shown that different
patterns of sulfation in HSPGs with similar core proteins lend
them different binding specificities (Kato et al., 1994; Sanderson
et al., 1994). Hence the concerted action of enzymes confers
highly variable patterns of sulfation to HS chains, thus driving
their complexity and micro-heterogeneity (Shriver et al., 2012;
Thacker et al., 2014). Importantly, data suggest that GAG chain
sulfation does not go to completion on sulfated polysaccharide
chains, yielding alternate highly sulfated domains (NS domains)
and regions showing low or no sulfation (NA domains) (Sarrazin
et al., 2011).
The sulfation pattern of most HSPGs changes during
development, thus modifying their binding specificities
(Nurcombe et al., 1993; Brickman et al., 1998; Yabe et al.,
2005), a process playing a critical role in nervous system
development (Irie et al., 2002; Bülow and Hobert, 2004). HS
modifications dynamically evolve during zebrafish development
(Cadwallader and Yost, 2006a,b, 2007; Zhang et al., 2009).
Studies in zebrafish have demonstrated a critical requirement
for HS in axon pathfinding during development (Lee et al.,
2004; Kim et al., 2007; Kastenhuber et al., 2009; Wang et al.,
2012; Poulain and Chien, 2013). Chemical disruption of HS
and CS biosynthesis in early zebrafish development leads to
brain disorganization (Beahm et al., 2014). However, the specific
binding motifs for many heparin-binding proteins remain to
be defined (Thacker et al., 2014). Full knowledge of HS-protein
interactions has important therapeutic implications. Surfen, a
non-specific heparan sulfate antagonist interferes with numerous
biological processes, showing potential as a therapeutic agent.
The properties of surfen ranges from anti-inflammatory
(Warford et al., 2018) and immuomodulatory (Warford et al.,
2014) to suppression of stem cell differentiation (Huang et al.,
2018), inhibition of HIV type 1 infection (Roan et al., 2010) and
rescue of tauopathy in a zebrafish model (Alavi Naini et al., 2018).
However, non-specificity limits the beneficial effects of surfen.
Surfen is reported to decrease neuroinflammation through
HSPGs while increasing both the beneficial and harmful CS
proteoglycans involved in remyelination (Warford et al., 2018).
Thus complete knowledge of the PG interactome promotes
development of specific therapies targeting harmful intractions
and/or enhancing beneficial ones.
TAU AND TAUOPATHIES
Tauopathies are neurodegenerative disorders characterized
by microtubule-associated protein tau (MAPT)
hyperphosphorylation and aggregation into paired helical
filaments (PHFs) or straight filaments (SFs), forming
neurofibrillary tangles (NFTs) in brain. Unlike amyloid-beta
(Aβ) aggregates, which are specifically detected in AD patients,
tau tangles are found in many neurodegenerative disorders such
as corticobasal degeneration (CBD), progressive supranuclear
palsy (PSP), Pick’s disease, dementia pugilistica, frontotemporal
dementia with parkinsonism linked to chromosome 17
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(FTDP-17), and many others including AD (Alavi Naini and
Soussi-Yanicostas, 2015). MAPT gene mutations are identified
in a number of tauopathies. The mutations alter the amino
acid sequence of tau, disrupt splicing or both (Alavi Naini and
Soussi-Yanicostas, 2015). AD and other dementias are currently
major challenges for health care systems, and major public
health priorities worldwide, for which there is an unmet need for
disease-modifying treatments (Frankish and Horton, 2017).
The tau protein is identified as a microtubule-associated
protein (MAP) with a wide range of potential functions. In
the adult human CNS six different tau isoforms are expressed
(Goedert et al., 1989b). They are generated via alternative
splicing of a single MAPT gene located on chromosome
17q21.31 and comprising 16 exons (Neve et al., 1986). Tau
isoforms range in length from 352 to 441 amino acids,
with a molecular weight of 45–65 kDa. The exons E1,
E4, E5, E7, E9, E11, E12 and E13, are included in all
tau isoforms. Tau isoforms are differentiated by three (3R)
or four (4R) carboxy-terminal tandem repeats of 31 amino
acids, which are designated as microtubule-binding domains
(MBDs). These repeated domains, which show strong sequence
conservation, are encoded by exons E9, E10, E11, and E12, the
exclusion or inclusion of exon 10 generates the 3R or 4R tau
isoforms, respectively (Goedert et al., 1989a,b; Andreadis et al.,
1992).
The main functions recognized for tau are microtubule
stabilization and polymerization. Microtubules are part of the
eukaryotic cytoskeletal framework and are primarily composed
of α- and β-tubulin, forming tubular polymers. Microtubules
are essential for cytoskeletal maintenance and intracellular
transport (Nogales, 2001). Tau mutations alter their affinity for
interaction and binding with microtubules (Alavi Naini and
Soussi-Yanicostas, 2015). Tau is able to bind to the outside
and probably to the inside of microtubules, while the N- and
C-terminal regions project outward (Kar et al., 2003; Santarella
et al., 2004). The tandem repeat sequences in the (MBD)
provide a net positive charge that interacts directly with the
negatively charged residues of tubulin (Kar et al., 2003; Jho et al.,
2010). The 4R-tau isoforms have higher affinity for binding to
microtubules than 3R-tau and are more efficient at promoting
microtubule assembly, likely due to the presence of the inter-
repeat sequences between the first and second microtubule-
binding repeats, which possess over twice the binding affinity of
any individual microtubule-binding repeat (Goedert and Jakes,
1990; Goode and Feinstein, 1994).
Tau alterations as biomarkers for dementia have mainly been
studied in AD. The amount of total tau (T-tau) in CSF correlates
with the intensity of neurodegeneration (Gao et al., 2018)
and hyperphosphorylated tau (P-tau) levels in CSF correlate
with hippocampal atrophy in prodromal AD (De Leon et al.,
2006; Fagan and Holtzman, 2010). Interestingly, Aβ peptide
accumulation does not correlate with neurodegeneration in
prodromal AD (Iaccarino et al., 2018). Moreover the mean
content of abnormally phosphorylated tau from several brain
regions in individual AD patients closely correlates with disease
severity (Holzer et al., 1994). These observations along with tau
mutations responsible for a number of tauopathies, highlight
the importance of tau alterations as therapeutic targets in
tauopathies.
ROLE OF HEPARAN SULFATE (HS) IN
TAUOPATHIES
In 1855 Virchow reported the presence of polysaccharides
in amyloid deposits in brain (Virchow, 1855). In 1942
Hass characterized the polysaccharides in amyloid lesions as
sulfated amino-sugar based polysaccharides, later called heparin-
like glycosaminoglycans (GAGs), and then heparan sulfate
proteoglycans (HSPGs) (Hass, 1942). Tauopathies are amyloid
disorders (Iadanza et al., 2018). Amyloid disorders are a diverse
group of protein-misfolding disorders (PMDs) characterized by
disease-specific protein aggregates containing heparan sulfate
proteoglycans (HSPGs) in most cases (Ancsin, 2003; Nishitsuji
and Uchimura, 2017).
The association of GAGs with protein aggregates in
Alzheimer’s disease (AD) and other tauopathies was described
decades ago in the literature (Kato et al., 1991; Su et al.,
1992; DeWitt et al., 1993, 1994). Further investigations
demonstrated that sulfated GAGs played a critical role in
tau hyperphosphorylation and aggregation, but also amyloid
precursor protein (APP) cleavage and the resulting Aβ peptide
fibrillization (Fraser et al., 1992; Brunden et al., 1993; Goedert
et al., 1996; Hasegawa et al., 1997; Scholefield et al., 2003;
Beckman et al., 2006). However, the nature of the sulfated GAGs
involved in these processes remained unclear. In particular,
GAG-tau interactions have received little attention as potential
therapeutic targets.
Heparan sulfate proteoglycans are associated with both
amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) in
Alzheimer’s disease (AD) (Snow et al., 1990; Kato et al., 1991;
Perlmutter et al., 1991; Perry et al., 1991; Su et al., 1992), the most
frequent form of tauopathy (Hernández et al., 2018). While the
principal HSPGs accumulating in the AD-associated aggregates
are membrane-associated HSPGs, the presence of perlecan (a
non-membrane-associated HSPG) in Aβ deposits is debated
(Van Gool et al., 1993; Snow et al., 1994; Van Horssen et al.,
2002). Specifically, the initially reported association of perlecan
with Aβ plaques and neurofibrillary tangles in AD was later
challenged because of the cross-reactivity of the antibodies used
(Verbeek et al., 1999). Perlecan is increased in AD brains (Liu
et al., 2016). However, a study of the perlecan mRNA levels in
the hippocampus of AD patients and age-matched controls has
shown similar expression levels (Maresh et al., 1996), and mice
overexpressing the perlecan core protein did not develop plaques
or tangles (Hart et al., 2001). Agrin is strongly expressed in the
hippocampus and amygdala (Bowe and Fallon, 1995; Donahue
et al., 1999), two areas strongly affected in AD (Braak and Braak,
1991). Agrin is the major HSPG associated with both Aβ plaques
and tau-containing NFTs in AD (Verbeek et al., 1999; Cole and
Liu, 2006). Last, heparanase (HPSE) is overexpressed in brain
areas showing degeneration in AD as measured by RT-PCR
(García et al., 2017), suggested be a protective mechanim. Thus
membrane-associated HSPGs provide a link between the two
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major hallmarks of AD, Aβ plaques and NFTs. This suggests that
the membrane-associated HSPGs might be involved in processes
upstream of AD lesions.
In many neuropathies, abnormal HSPG accumulations are
often observed at early stages of the disease. HSPGs accumulate
in neuronal cell bodies in Down syndrome patients years before
the first clinical symptoms of dementia occur. HSPGs are also
associated with Aβ deposits in the early stages of AD. Specifically,
HSPGs are associated with both immature diffuse Aβ plaques
(Snow et al., 1990, 1994; Su et al., 1992; Cotman et al., 2000) and
hyperphosphorylated tau aggregates, during the earliest stages of
neurofibrillary pathology (Spillantini et al., 1999). Interestingly,
in this situation HSPG staining is more intense than that of tau,
suggesting that HSPGs play a role in initiation of disease.
In 1996 in vitro biochemical investigations demonstrated that
interactions between heparin and tau protein led to the assembly
of tau into NFT-like filaments (Goedert et al., 1996). Moreover,
sulfated motifs on the GAG chain are critical for tau aggregation,
as the non-sulfated hyaluronic acid does not enhance tau
polymerization (Arrasate et al., 1997). Aside from structural
changes, heparin was also shown to markedly stimulate the
phosphorylation of tau by different protein kinases, leading to tau
hyperphosphorylation, a key feature of tauopathies. In particular,
tau phosphorylation by cdc28, cAMP-dependent protein kinase,
GSK3b and several stress-activated protein kinases (SAP kinases)
are markedly stimulated in vitro by heparin (Mawal-Dewan
et al., 1992; Brandt et al., 1994; Yang et al., 1994; Goedert et al.,
1997; Hasegawa et al., 1997). Heparin also prevents tau binding
to taxol-stabilized microtubules and promotes disassembly of
microtubules formed by tau and tubulin, suggesting that highly
sulfated GAGs compete with microtubules for tau binding
(Goedert et al., 1996). However, further research showed that
the effect of heparin on tau was mimicked by several GAGs and
depended on their degree of sulfation: highly sulfated dextran
sulfate, pentosan polysulfate and heparin exerted a marked effect,
while a number of intermediately sulfated GAGs such as HS,
CS and DS had a moderate effect, and non-sulfated dextran
and hyaloronic acid had no effect (Hasegawa et al., 1997).
Interestingly, the concentration of sulfated GAGs required to
stimulate tau phosphorylation was lower than that required for
tau assembly and aggregation (Hasegawa et al., 1997), suggesting
that tau phosphorylation may precede its assembly into NFTs.
The increased phosphorylation and aggregation of tau observed
in tauopathies may involve a substrate modulator effect of GAGs
on tau conformation, as previously shown in other biological
contexts (Faucher et al., 1988; Abdel Ghany et al., 1990).
Association of HSPGs with proteins can lead to
conformational changes in the bound proteins, as demonstrated
by the allosteric effect of heparin on anti-thrombin. Heparin
induces a conformational change in tau (Paudel and Li, 1999;
Sibille et al., 2006; Elbaum-Garfinkle and Rhoades, 2012), and
heparin-induced conformational changes have been shown to
expose previously masked tau phosphorylation sites (Zheng-
Fischhöfer et al., 1998; Paudel and Li, 1999; Yoshida and Goedert,
2012). Electron microscopy data has provided evidence that
sulfated GAGs present in tau aggregates affect paired helical
filament (PHF) conformation: treatment of PHF-tau extracted
from AD patients with heparinase or chondroitinase resulted in
untwisting of PHF filaments (Arrasate et al., 1997). Furthermore,
treatment of PHF-tau tangles with heparinase alters their
immunodecoration properties, suggesting conformational
changes upon heparinase treatment (Hernández et al., 2002).
Specifically, heparin interacts with the second (R2) and third
(R3) repeat regions of the tau microtubule-binding domain
(Sibille et al., 2006). More recently, a small domain located in the
N-terminal region of the R2 repeat was identified as critical for
binding (Mukrasch et al., 2005; Zhao et al., 2017). Interestingly,
Hasegawa et al. (1997), have suggested that sequence differences
among moderately sulfated GAGs likely play a role in their
interaction with tau (Hasegawa et al., 1997), as the overall level
of sulfation cannot account for the observed effects. This further
suggests that specific sulfated sequences on GAGs are required
for interaction with tau.
Most importantly, cell surface HSs also act as receptors for
Aβ (Kanekiyo et al., 2011) and extracellular tau aggregates, likely
mediating a prion-like propagation of the pathology (Holmes
et al., 2013), as reflected by the stages defined by Braak and Braak
(1991). Membrane-associated heparan sulfate is involved in cell
surface binding, uptake and internalization of tau seeds (Holmes
et al., 2013) suggesting that propagation of tau seeds can also
be blocked by pharmacological targeting of cell surface HSPGs.
This approach may slow the progression of tauopathies (Holmes
and Diamond, 2014). Alteration of heparan sulfate structure with
aging may also be implicated in neurodegeneration. In particular,
HS is important for adult neurogenesis by modulating FGF
signaling; age-related alteration of HS binding properties in the
hippocampus (Huynh et al., 2012), significantly compromises
local regenerative capacities (Yamada et al., 2017). Membrane-
bound HS, such as syndecans and glypicans are critical for
regulation of neurogenesis (Yu et al., 2017).
Heparan sulfate has emerged as a potential multiplayer in
tau pathology. HS is potentially implicated in the initiation
and propagation of tau pathology and may play a role in
limiting regenerative potential in dementia-susceptible regions.
Further studies are needed to elucidate the role of different
HSPGs in tauopathies. Memebrane-bound HS, mostly syndecan-
3, syndecan-4 and glypican-3, are increased in AD brain (Liu
et al., 2016). Particular attention should be paid to processes
defining regional susceptibility to tauopathy.
ZEBRAFISH FOR DRUG DISCOVERY IN
TAUOPATHIES
The zebrafish (Danio rerio), is a well-established model for
the study of developmental biology, gene function and human
diseases. As a vertebrate, it is closer to humans than invertebrate
models, such as nematodes and fruit flies, and offers many
advantages over invertebrate and other alternative vertebrate
models.
The zebrafish is particularly well-suited for forward and
reverse genetic and high-throughput functional studies. Major
advantages of zebrafish include a precisely characterized genome
with genes showing 50–80% sequence similarities with their
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human orthologs. Orthologous counterparts of many genes
relevant to tauopathies or specifically to Alzheimer’s disease
are identified in zebrafish. The zebrafish has undergone an
ancient genome duplication followed by loss of many duplicated
genes. Two paralogs of the human MAPT gene, mapta and
maptb, have been identified in zebrafish. Interestingly, in early
developmental stages mapta transcripts contain predominantly
4-6 Rs, while most maptb transcripts contain 3Rs (Chen et al.,
2009). In embryonic stages, the expression of mapta and maptb
show a positive correlation with sex-linked ubiquitin-specific
peptidase 9 (USP9) (Köglsberger et al., 2017). In the adult
zebrafish brain, hypoxia is reported to shift splicing of mapta and
maptb transcripts toward 4-6 R isoforms (Moussavi Nik et al.,
2014). Orthologs to human APOE (apoea and apoeb), APP (appa
and appb) and the APP cleaving complex are also identified in
zebrafish (Newman et al., 2014).
Further advantages of the zebrafish include low cost, high
fecundity, short generation time, external fertilization, external
embryonic development and embryo transparency allowing easy
manipulation and visualization. This small fish is particularly
advantageous for the study of the nervous system as its
small brain size facilitates imaging. Despite differences in
CNS development, anatomy and chemistry (Panula et al.,
2010), overall brain organization (Rupp et al., 1996) with
neuroanatomical (Rink and Wullimann, 2004; Mueller and
Wullimann, 2009) and neurochemical (Mueller et al., 2004)
pathways show striking similarities in zebrafish and humans.
The adult zebrafish also displays high-order behaviors such
as memory, social contacts and conditioned responses (Guo,
2004). In addition, the transparency and small size of its brain
allow recording of neuronal activity by the recently developed
molecular sensors such as genetically encoded calcium indicators
or voltage sensors (Lin and Schnitzer, 2016).
Microinjection of antisense morpholino oligonucleotides
(MOs) into one-cell stage zebrafish embryos allows rapid, simple
and specific reverse genetic studies by inhibition of mRNA
splicing or translation (Nasevicius and Ekker, 2000; Eisen and
Smith, 2008). Efficient transgenesis methods and large-scale
mutagenesis screens, mRNA injection, and genomic editing tools
such as the CRISPR/cas9 approach are developed in zebrafish
(Prykhozhij et al., 2018). Zebrafish embryos are also suitable
for large-scale chemical screening to identify novel therapeutic
targets and compounds. Whole cell, tissue or organism assays
are twice as often successful in drug discovery efforts than
target-based assays, and the ideal assay settings are whole
organism assays. Phenotypic screens, particularly in CNS drug
discovery, have been markedly more efficient in identifying novel
therapeutic entities than target-based assays in recent pre-clinical
studies (1999–2008) (Swinney and Anthony, 2011). Zebrafish
embryos have also been used to study the potential toxicity
of an imaging probe for NFTs (Anumala et al., 2013) and a
neuroprotective agent for AD (Torres et al., 2014).
Recent successes in drug discovery in zebrafish rely on
conserved physiological pathways and drug metabolism. Here we
cite two examples of such discoveries. Clemizole, approved by the
FDA, has been found to inhibit seizures in a zebrafish phenotypic
screen for antiepileptic drugs (Baraban et al., 2013). Zebrafish
larval assays have also revealed an FDA-approved substance that
protects against the ototoxicity of aminoglycoside, which enters a
phase I clinical trial this year (Smuga-Otto, 2018).
The analogy of brain structure and neuronal subtypes between
zebrafish and humans, together with expression of key tau
phosphorylating kinases, makes the zebrafish an attractive model
organism for investigating tau pathology (Santana et al., 2012).
Several transgenic zebrafish models of tauopathy expressing
either the wild-type or mutant human tau protein are generated.
These models represent the proof of concept that zebrafish
models of tauopathy recapitulate key aspects of tau pathology.
First, a zebrafish model transiently expressing a mutant human
tau protein fused to GFP reproduced the cytoskeletal pathology
in the brain including the accumulation of tau in NFT-
like aggregates and the presence of hyperphosphorylated tau
(Tomasiewicz et al., 2002). The hybrid protein was under the
control of the pan-neuronal gata2 promoter, which is expressed
in the brain, retina and spinal cord and shows mosaic expression.
This study demonstrated the conservation of pathways involved
in tauopathy in zebrafish, making it possible to robustly model
the pathology in this species.
More recently, a stable zebrafish transgenic line was produced
that expresses the human 4-repeat tau under the control of
the zebrafish enolase-2 (eno2) promoter. The utility of the eno2
promoter lies in its expression, which starts in differentiated
neurons and persists into adulthood. Tau deposits resembling
NFTs were found within neuronal cell bodies and proximal
axons in brain regions relevant to PSP (Bai et al., 2007; Bai and
Burton, 2011). Later, a stable zebrafish transgenic line expressing
the human tau protein carrying the tauP301L mutation linked
to frontotemporal dementia (FTD) under the control of the
zebrafish pan-neuronal HuC promoter was generated (Paquet
et al., 2009). In this model, the Tg[HuC::hTauP301L/DsRed],
the vector system allows expression of the mutated human
tau P301L along with simultaneous expression of DsRed
fluorescent reporter, facilitating the identification of the mutated
tau expressing neurons. Tg[HuC::hTauP301L/DsRed] develops
spinal motoneuron axon extention and elongation defects and
neurodegeneration in early developmental stages and as a
consequence deficits in the escape response reflex. Similar
defects were also observed in zebrafish larvae expressing the
mutant A152T tau protein (Lopez et al., 2017). The chronic
expression of the P301L mutant tau into adulthood has also
been recently examined in zebrafish (Cosacak et al., 2017).
Focusing on the adult zebrafish brain, Cosacak et al reported
tau hyperphosphorylation in the telencephalon. However, the
authors did not find tauopathy-related symptoms in the
telencephalon, such as formation of neurofibrillary tangles. This
is in contrasts with another report (Bai and Burton, 2011) on
tau mislocalization and tau-laden neurofibrillary like structures
in tau transgenic adult zebrafish brain.
The observed discrepancies may be due to the specific brain
regions studied, telencephalon (Cosacak et al) vs. optic tectum
and brainstem (Bai and Burton), or different transgenic systems
or labeling methologies used. However, the possible resistance
of adult zebrafish telencephalon to tauopathy is an interesting
avenue of investigation that may reveal potential protective
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mechanisms. Moreover, HS plays a role in nervous system
regeneration (Fuller-Carter et al., 2015; Yamada et al., 2017).
High regenerative capacities in zebrafish (Gemberling et al., 2013)
makes the organism a suitable model to study the implication of
HS in regenerative processes.
A transient expression system is also established that expresses
either full-length or truncated zebrafish 3R or human 4R
tau, fused to GFP, under the control of HuC promoter (Wu
et al., 2016). The expression of all constructs was found to
be toxic, causing significant neurodegeneration. Using this
experimental system enhancing an anti-apoptotic, anti-oxidative
or neurotrophic mechanisms, was found to be protective against
neurodegeneration.
The zebrafish offers numerous, diverse advantages as an
animal model for the study of nervous system pathology.
Numerous genes orthologous to those involved in tauopathies
have been identified in the zebrafish. Experiments on zebrafish
have confirmed the conservation of essential pathways between
humans and the zebrafish that enable it to model tau pathology.
Specific brain regions in the zebrafish are reported to bear
resistance to NFT formation, possibly due to high regenerative
capacities. Elucidation of these mechanisms, in particular the role
of HS in the pathological vs. protective or regenerative processes
in zebrafish will help identify potential pathways and targets to
prevent or treat tau pathology.
THERAPEUTIC APPROACHES
TARGETING HSPGS IN TAUOPATHIES
A better knowledge of HS-protein interactions has huge
therapeutic implications for human pathologies (Capila and
Linhardt, 2002; Lindahl, 2007). The primary therapeutic
approach based on targeting PGs/GAGs in tauopathies
consists of treatment with exogenous GAGs or GAG mimetics.
Administration of exogenous GAGs is believed to competitively
inhibit the harmful processes mediated by endogenous GAGs
(Wang and Ding, 2014). A summary of therapeutic approaches
involving exogenous GAGs and GAG mimetics is presented in
Table 1. Indeed, LMW heparin oligomers efficiently inhibit the
stimulatory effect of heparin on APP secretion, and inhibit the
binding of heparin to Aβ1−28 peptide in vitro (Leveugle et al.,
1998). However, large sulfated GAGs such as heparin and DS
inhibit the binding of HSPGs to APP in vitro (Narindrasorasak
et al., 1991). Several polysulfated GAGs and synthetic sulfate-
containing compounds such as the Aβ-binding sulfonated dye
Congo Red, along with several other sulfonated dyes, have
been found to attenuate the neurotoxic effects of Aβ25−35 and
Aβ1−40 in vitro (Pollack et al., 1995a,b). Moreover, several small
anionic substances with sulfonate and sulfate residues efficiently
decrease Aβ deposition (Kisilevsky et al., 1995). Accordingly,
arrays of LMW GAGs are developed as competitive inhibitors
of PG interactions (Gervais et al., 2001). Neuroparin (C3), an
LMW GAG derivative of heparin, has been shown to have
neuroprotective and neuroreparative properties in several animal
models of AD (Dudas et al., 2008). Interestingly, neuroparin
is reported to attenuate the abnormal tau immunoreactivity
(representative of an AD-related conformational alteration of
tau) in rat hippocampus following unilateral injection of Aβ25−35
into the amygdala (Dudas et al., 2002). In addition, this abnormal
Aβ25−35 induced tau immunoreactivity was fully prevented
following chronic subcutaneous injections of the LMW GAG
ceroparin (Walzer et al., 2002). Heparin-like oligosaccharides
reduce uptake of tau oligomers limiting their infectivity (Wang
et al., 2018).
Another ionic compound, tramiprosate (3-amino-1-
propanesulfonic acid; 3APS; AlzhemedTM), has been shown
to bind preferentially the soluble Aβ peptide, maintain Aβ
peptide in a soluble conformation, and reduce Aβ burden
in TgCRND8 mice, a transgenic AD model that develops
early-onset and aggressive brain Aβ amyloidosis (Gervais et al.,
2007). However, in November 2007, tramiprosate was rejected
for further pharmaceutical development because of a lack of
proven efficacy in a phase III human clinical trial (Carter et al.,
2010). However, while clinical trials of tramiprosate in mild-
to-moderate AD have not shown therapeutic efficacy, post-hoc
analyses have shown some significantly positive outcomes on
secondary endpoints and in some particular subgroups of
patients (Aisen et al., 2011; Caltagirone et al., 2012). In particular,
the disease-modifying potential is highlighted in APOE4 allele
carrier patients by the observed cognitive benefits (Caltagirone
et al., 2012; Abushakra et al., 2017).
The classic strategies aimed at HSPGs are mostly tested in
AD where benefits are observed in distinct patient subgroups.
In these strategies, APP and Aβ (not tau) are mostly studied
as targets. An alternative approach consists in targeting HS
sulfation. Recently, overexpression of several HS biosynthetic
enzymes such as 3-O-sulfotransferase-2 (3ost2 or Hs3st2)
was demonstrated in the hippocampus of AD patients.
Inactivation of the zebrafish ortholog of the HS chain modifier
enzyme Hs3st2 significantly decreased tau hyperphosphorylation
and tau-related neuropathology in vitro and in vivo in
the Tg[HuC::hTauP301L/DsRed] zebrafish model of tauopathy
(Sepulveda Diaz et al., 2015). An additional approach consists
of treatment with heparan sulfate antagonist molecules. In a
recent proof of concept study a rescue of neuronal abnormalities
upon treatment with surfen and oxalyl surfen was observed
in the Tg[HuC::hTauP301L/DsRed] zebrafish model (Alavi Naini
et al., 2018). Figure 1 summarizes the two approaches in
Tg[HuC::hTauP301L/DsRed] zebrafish.
3-O-Sulfation in HS chains forms binding sites for HSPG
binding proteins. However, biochemical characterization of this
rare modification among an array of other sulfated groups
requires large sample quantities, and shortage of material for
studying 3-O-sulfation has so far hampered work on these
sulfated motifs. So far six HSPG-binding proteins have been
shown to require 3-O-sulfation for their association with GAG
chains (Thacker et al., 2014).
The addition of a 3-O-sulfate group is one of the last chain
modifications in HS biosynthesis (Zhang et al., 2001a,b). This
modification is a rare and discrete modification confined to a
limited number of chains when it occurs at all, and its prevalence
among naturally occurring HSs is largely unknown (Thacker
et al., 2014). The 3-O-sulfate group was initially identified while
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TABLE 1 | Classic strategies targeting HSPGs in tauopathies.
Category Names Targets Settings/Organisms Outcomes References
Sulfated
glycosaminoglycans
(GAGs)
Conventional GAGs Heparin, dextran sulfate
and other GAGs
APP/Aβ In vitro, PC12 cells Inhibition of HSPG
binding to APP
Narindrasorasak et al., 1991;
Leveugle et al., 1994
Heparin analogs BACE1 In vitro BACE1 inhibition Patey et al., 2006, 2008
Low molecular weight
(LMW) heparins
Heparin
oligosaccharides
APP/Aβ In vitro, Human Inhibition of the
stimulatory effect of
heparin on APP
secretion and heparin
binding to Aβ1−28
Leveugle et al., 1998
Tau Neuroblastoma culture Reduction in cellular
uptake and cytotoxicity
of tau oligomers
Wang et al., 2018
Enoxaparin/Dalteparin Aβ In vitro Disassembley of Aβ40
fibrils
Zhu et al., 2001
Certoparin/Neuroparin
(C3)
Aβ/Tau Rat Reduction in tau
abnormal conformation
in hippocampus,
stimulated by Aβ25−35
intra-amygdaloid
injection
Walzer et al., 2002/ Dudas
et al., 2002, 2008
Enoxaparin Aβ APP23 mice Decrease in Aβ brain
concentration,
deposition and reactive
astrocytosis
Bergamaschini et al., 2004
APPswe/PS1dE9 mice Improvement of spatial
memory, decrease in
Aβ deposition if treated
in early stages of Aβ
accumulation
Timmer et al., 2010
Low molecular weight anionic sulfonate
or sulfate compounds
Congo red and analogs Aβ PC12/Hela cells Attenuation of Aβ25−35
and Aβ40 toxicity
Pollack et al., 1995b,a
Sodium
1,3-propanediol
disulphate
Aβ In vitro Disassembly of Aβ40
fibrils
Kisilevsky et al., 1995
Tramiprosate (3-amino-
1-propanesulfonic acid;
3APS; homotaurine;
AlzhemedTM)
Aβ TgCRND8 mice Significant reduction of
Aβ in brain and plasma,
reduction of Aβ plaques
in brain
Gervais et al., 2007
Humans: Phase II trial
in probable mild to
moderate AD
Satisfactory safety and
tolerability, significant
decrease of CSF Aβ42
levels, no cognitive
benefits
Phase III trial in mild to
moderate AD
No cognitive benefits,
post-hoc analyses:
decrease in loss of
hippocampal volume
Aisen et al., 2006
Cognitive benefits in
APOE4/4 patients
Abushakra et al., 2017
searching for sulfate group removing enzymes on heparin (Leder,
1980), and later confirmed with chemical, NMR and mass
spectrometry analyses (Meyer et al., 1981; Yamada et al., 1993).
The best-studied case of 3-O-sulfate group-dependent binding
is the association of anti-thrombin (AT) to heparin and HS.
Binding of heparin to AT induces conformational changes in the
protein that radically increase its catalytic activity (Rosenberg
and Damus, 1973; Huntington et al., 1996). The activated AT
then inactivates several proteases, including thrombin, factor
IXa, and factor Xa, which are involved in blood coagulation.
This is why heparin is used as a routine anticoagulant agent
in clinical practice. The characterization of AT binding sites
on the sulfated sugar chains is facilitated by their enrichment
in heparin, which is readily available commercially (Yamada
et al., 1993). The minimum AT binding site on heparin is a
pentasaccharide sequence with a critical 3-O-sulfated motif on
the middle N-sulfo-glucosamine residue (Thunberg et al., 1982;
Choay et al., 1983). In the absence of this 3-O-sulfate group, the
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FIGURE 1 | Combination of genetic (A) and pharmacological (B) approaches identified novel therapeutics for tauopathies using a zebrafish transgenic model of tau
pathology.
affinity of heparin to AT was markedly decreased, along with its
inhibitory effect on factor Xa (Atha et al., 1985, 1987).
3-O-Sulfated HSs at the cell surface also serve as entry
receptors for the herpes simplex envelope glycoprotein,
glycoprotein D (gD) (Shukla et al., 1999), and the binding
domain has been identified as an octosaccharide containing
a 3-O-sulfated motif (Liu et al., 2002). In a similar manner,
fibroblast growth factor 7 (FGF7) and fibroblast growth factor
receptors (FGFR) are thought to rely on 3-O-sulfated motifs
for binding to HS and heparin (McKeehan et al., 1999; Ye
et al., 2001; Luo et al., 2006). Moreover, 3-O-sulfation on
heparin/HS is suggested to mediate the binding of “cyclophilin
B” and “stabilin” (Vanpouille et al., 2007; Pempe et al., 2012).
Cyclophilin B promotes lymphocyte adhesion and migration
following binding to HS located at the cell surface (Allain et al.,
2002). Stabilins (1, 2) mediate heparin clearance in hepatic
sinusoidal endothelial cells (Hansen et al., 2005; Harris et al.,
2008).
Combination of genetic (A) (morpholino gene-KO)
(Sepulveda-Diaz et al., 2015) and pharmacological (B) (small
molecule) (Alavi Naini et al., 2018) approaches in the zebrafish
Tg[HuC::hTauP301L; DsRed] tauopathy model identified 3-OS-
sulfated HS as a therapeutic target for tauopathies and the
small molecules surfen and oxalyl surfen as novel therapeutic
candidates.
Alterations in the fine structure of GAGs have previously
been described in several pathological situations. The sulfate
moieties on GAG chains have been shown to contribute to
amylin fibrillization in islet amyloidosis (Castillo et al., 1998).
Furthermore, alteration of the O-sulfation pattern and specific
disaccharide compositions has been observed in amyloid-laden
liver and spleen tissues (Lindahl and Lindahl, 1997). An analysis
of the HSs in the cerebral cortex in AD and control subjects
demonstrated an alteration in N-sulfated residue distribution
in AD brain, with an increase in GlcNSO3 residues (Lindahl
et al., 1995). However, in studies of cerebral tissue the abnormal
HSs may have been diluted with normal HSs, as analyses were
performed on whole brains. In particular, alterations in specific
HSPG populations or modifications of small domains in HSPG
chains may have been hidden. Moreover, in AD, analysis of skin
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fibroblasts from patients revealed alterations in HS sulfation.
Zebrower and Kieras reported that cultured skin fibroblasts
from AD patients produced 30% more GlcA-GlcNSO3, and
40% less GlcA-GlcN-6-OSO3 compared to samples from age-
matched healthy individuals (Zebrower et al., 1992). Authors
suggested that an alteration in HS-sulfotransferase activity
was responsible for their observations (Zebrower and Kieras,
1993). Importantly, a critical requirement for the presence
of 6-O-sulfated disaccharide-containing HS in internalization
and spreading of infectious tau species has recently been
demonstrated (Rauch et al., 2018; Stopschinski et al., 2018).
6-O-Sulfation was also identified as critical for heparin-tau
interaction by surface plasmon resonance (SPR) and nuclear
magnetic resonance (NMR) spectroscopy (Zhao et al., 2017),
while the requirement for 3-O-sulfation was not investigated
in these recent studies. These studies together with studies
on 3-O-sulfation (Sepulveda-Diaz et al., 2015) support the
hypothesis that specific GAG chain sulfation mediated by a
combination of 2-, 3- and 6-O-sulfotransferases play a key role
in the physiopathology of tauopathies. Interestingly, hierarchical
sulfation of disaccharide residues allows 3-O-sulfated motifs to be
generated only on 6-O-sulfated domains of GAG chains.
Aside from hyperphosphorylation and aggregation of the tau
protein, the sulfated motifs on GAG chains have also been
shown to play a role in Aβ fibrillization and aggregation. This
was first suggested by Fraser and coworkers, based on X-ray
diffraction studies (Fraser et al., 1992). A later in vitro study
showed that the sulfated motifs on GAG chains directly bind
fibrillar Aβ (Gupta-Bansal et al., 1995). In addition, while removal
of N-sulfated motifs on heparin GAG chains slightly reduced
the heparin-induced Aβ fibril formation (Castillo et al., 1999),
removal of O-sulfates led to a significant loss of heparin-enhanced
Aβ fibrillization. Heparin enhancement of Aβ fibrillization was
significantly greater than that induced by HS, consistent with the
lower sulfate content in HS. By contrast, inorganic sulfate was
found to have no effect (Castillo et al., 1999).
In turn, Aβ peptides have been suggested to influence GAG
composition and localization (Miller et al., 1997; Timmer et al.,
2009). In particular, Aβ42 carrying the Dutch mutation has been
reported to induce cellular relocalization and production of
agrin and glypican-1 in vitro, together with altered glycosylation
and increased sulfate incorporation (Timmer et al., 2009).
Interestingly, the treatment of human brain pericytes (HBPs)
with Aβ42Dutch leads to the association of Aβ fibrils to cell surface
glypican-1 prior to their internalization (Timmer et al., 2009).
TGF-β enhancement of Aβ fibril formation is also suggested to
involve an increase in HSPG synthesis or chain modification
(Castillo et al., 1999). Aβ degradation takes place in the lysosomal
compartment (Li et al., 2012), the intracellular compartment
where HSPG degradation also occurs (Brauker and Wang, 1987;
Yanagishita and Hascall, 1992; Bame, 1993). Interestingly, Aβ
has been shown to inhibit the heparanase-mediated degradation
of GAGs and HSPGs in vitro (Bame et al., 1997), suggesting
that a similar process may hamper HSPGs degradation in vivo
in tauopathies, creating a scenario similar to that observed in
patients with mucopolysaccharidoses.
Apolipoprotein E (whose E4 allele is a major risk factor
in sporadic AD) promotes GAG sulfation in cultured
neuroblastoma cells, and this effect is greater for ApoE4
than ApoE3 (Bonay and Avila, 2001). The interaction between
HSPGs and apolipoprotein is necessary for the uptake of
apolipoprotein E-containing lipoprotein by low-density
lipoprotein (LDL) receptor related protein (LRP) by hepatocytes
in vitro. Lipoprotein uptake in neurons is also mediated by
the HSPG/LRP pathway (Mahley, 1996). Interestingly, apoE
has been shown to interact with HSPGs through a binding
site, which is structurally complementary to HS rich in N-
and O-sulfate groups (Libeu et al., 2001). Moreover, the
inhibitory effect of ApoE4 (not observed for ApoE3) on neurite
outgrowth in vitro is likely mediated by the HSPG/LRP pathway
(Bellosta et al., 1995). Moreover, a synthetic peptide that
contain the amino acid residues 141-155, together with a 22
kDa N-terminal thrombin-cleavage fragment of apoE display
significant toxicity to neurites from embryonic chick neurons
in vitro, with apoE4 fragments exhibiting greater toxicity than
apoE3. The toxic effect is likely mediated via the HSPG/LRP
pathway, and treatments antagonizing HS prevent neurite
degeneration (Crutcher et al., 1994; Marques et al., 1996). HSPG
acts jointly with LRP1 for cell surface binding and uptake of
Aβ (Kanekiyo et al., 2011). Finally, ApoE (Li et al., 2012) and
LRP (Fuentealba et al., 2010) promote lysosomal trafficking of
Aβ. ApoE acts in an isoform-dependent manner, with apoE3
enhancing Aβ trafficking and degradation more efficiently
than apoE4 (Li et al., 2012). These observations support the
hypothesis that a defect in the metabolism of HS orchestrated
by Aβ and apoE may play a role in the physiopathology of
tauopathies.
The internalization of HS in the intracellular space has
been described in several pathological situations (Cole and
Liu, 2006). The intracellular accumulation of HS long before
detection of tau pathology in neurons in AD and in Down
syndrome was described decades ago (Snow et al., 1990;
Goedert et al., 1996). However, their involvement in the
series of events leading to the abnormal tau phosphorylation
and neurodegeneration has been largely disregarded,
possibly because of the paradigm confining the biological
roles of HSPGs to the extracellular space (Shriver et al.,
2012).
The association of sulfated GAGs with tau in neurons has
long been puzzling and was seen to result from leakage of newly
synthesized sulfated GAGs from intracellular organelles such as
Golgi apparatus, endosomes and lysosomes (Díaz-Nido et al.,
2002). Interestingly, under two distinct pathological situations
in neuroblastoma cultures, expression of human tauP301L
protein and exposure to oxidative stress, HS was localized in
intracellular space. An intense intracellular uptake of membrane-
associated HS and the concomitant hyperphosphorylation of
the tau protein were observed (Sepulveda Diaz et al., 2015).
These findings point to a possible altered metabolism and
distribution of sulfated HS in tau-related neuropathologies.
Regarding the molecular mechanisms linking 3-O-sulfated HSs
and tau abnormal phosphorylation, in vitro data suggest
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that the sulfated GAGs bind to tau and not to the GSK3β
tau-kinase (Sepulveda Diaz et al., 2015). Accordingly, in the
presence of heparin (a highly sulfated HS), tau rapidly undergoes
conformational changes that allow kinase access to epitopes
otherwise inaccessible for phosphorylation (Hasegawa et al.,
1997; Zheng-Fischhöfer et al., 1998; Paudel and Li, 1999; Sibille
et al., 2006; Yoshida and Goedert, 2012). The substrate modulator
effect of 3-O-sulfated HS motifs further supports the hypothesis
that these sulfated polysaccharides act as molecular chaperones
able to induce key conformational changes on tau protein and
triggering its phosphorylation at newly unmasked tau residues.
The hypothesis is further supported by the observation of
an increase in hippocampal 3-O-sulfation with aging (Huynh
et al., 2012). Recently, a GAG sulfotransferase inhibitor has
been identified (Cheung et al., 2017) that sets a basic scaffold
for the future development of highly specific and potent
sulfotransferase inhibitors, which are promising candidates as
potential therapeutics for tauopathies.
CONCLUSION
Heparan sulfate-protein interactions are emerging as potential
therapeutic targets in tauopathies. Previous work suggest
a multifactorial role played by GAGs in the pathogenesis
of tauopathies. Increased biosynthesis, internalization and/or
decreased degradation of HS GAGs, or alterations in HS
chain modifications likely contribute to tauopathies. These
observations raise the question of whether specific motifs on HS
chains are involved in binding to tau and induction of misfolded
states. The zebrafish has recently emerged as an attractive animal
model for Alzheimer’s disease research and provides an ideal tool
for drug screening prior to clinical testing in mammals. Thanks
to this small fish, HS is targeted in tau pathology by two different
approaches. A critical requirement for 3-O-sulfated HS in tau
pathology was discovered and HS antagonists (surfen and oxalyl
surfen) were identified as efficient therapeutic candidates. 6-O-
sulfated HS motifs have recently been identified as critical for
tau seed internalization. 3-O-sulfation, a fine chain modification,
is only generated in 6-O-sulfated regions. Together, these recent
findings strengthen the hypothesis of distinct HS sequences
implicated in tau misfolding, hyperphosphorylation, aggregation
and propagation. These findings are steps toward defining of
specific HS targets in tauopathies.
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